Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

ClinicalTrials.gov ID: NCT04501666

Public ClinicalTrials.gov record NCT04501666. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis

Study identification

NCT ID
NCT04501666
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Galderma R&D
Industry
Enrollment
286 participants

Conditions and interventions

Interventions

  • Nemolizumab 30 mg Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 10, 2020
Primary completion
Nov 10, 2022
Completion
Feb 20, 2023
Last update posted
Jul 9, 2024

2020 – 2023

United States locations

U.S. sites
38
U.S. states
19
U.S. cities
35
Facility City State ZIP Site status
Galderma Investigational Site Birmingham Alabama 35233
Galderma Investigational Site Birmingham Alabama 35244
Galderma Investigational Site Los Angeles California 90045
Galderma Investigational Site Sacramento California 95815
Galderma Investigational Site San Diego California 92121
Galderma Investigational Site San Diego California 92130
Galderma Investigational Site Santa Monica California 94404
Galderma Investigational Site Delray Beach Florida 33484
Galderma Investigational Site Hollywood Florida 33021
Galderma Investigational Site Largo Florida 33770
Galderma Investigational Site Miami Florida 33125
Galderma Investigational Site Pembroke Pines Florida 33028
Galderma Investigational Site Tampa Florida 33607
Galderma Investigational Site Columbus Georgia 31904
Galderma Investigational Site Macon Georgia 31217
Galderma Investigational Site Chicago Illinois 60613
Galderma Investigational Site Lake Bluff Illinois 60044
Galderma Investigational Site Topeka Kansas 66614
Galderma Investigational Site Baltimore Maryland 21231
Galderma Investigational Site Ann Arbor Michigan 48109
Galderma Investigational Site Saint Joseph Missouri 64506
Galderma Investigational Site St Louis Missouri 63110
Galderma Investigational Site New York New York 10065
Galderma Investigational Site High Point North Carolina 27262
Galderma Investigational Site Raleigh North Carolina 27617
Galderma Investigational Site Cleveland Ohio 44106
Galderma Investigational Site Norman Oklahoma 73071
Galderma Investigational Site Philadelphia Pennsylvania 19103
Galderma Investigational Site Philadelphia Pennsylvania 19104
Galderma Investigational Site Johnston Rhode Island 02919
Galderma Investigational Site Providence Rhode Island 02903
Galderma Investigational Site Knoxville Tennessee 37909
Galderma Investigational Site Austin Texas 78738
Galderma Investigational Site Bellaire Texas 77401
Galderma Investigational Site Laredo Texas 78401
Galderma Investigational Site Salt Lake City Utah 84117
Galderma Investigational Site Springville Utah 84663
Galderma Investigational Site Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04501666, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 9, 2024 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04501666 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →